CN104606284A - New uses of Ajuga ciliata Bunge extract - Google Patents
New uses of Ajuga ciliata Bunge extract Download PDFInfo
- Publication number
- CN104606284A CN104606284A CN201310541149.6A CN201310541149A CN104606284A CN 104606284 A CN104606284 A CN 104606284A CN 201310541149 A CN201310541149 A CN 201310541149A CN 104606284 A CN104606284 A CN 104606284A
- Authority
- CN
- China
- Prior art keywords
- herba ajugae
- ajuga ciliata
- extract
- inflammatory disease
- chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001533451 Ajuga ciliata Species 0.000 title claims abstract description 58
- 239000000284 extract Substances 0.000 title claims abstract description 55
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims abstract description 37
- 230000001684 chronic effect Effects 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 21
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 17
- 230000008595 infiltration Effects 0.000 claims abstract description 16
- 238000001764 infiltration Methods 0.000 claims abstract description 16
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 11
- 230000006020 chronic inflammation Effects 0.000 claims abstract description 8
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 5
- 230000007774 longterm Effects 0.000 claims abstract description 5
- 208000031737 Tissue Adhesions Diseases 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 206010020880 Hypertrophy Diseases 0.000 claims description 16
- XUWSHXDEJOOIND-YYDKPPGPSA-N (1s,4as,5r,7s,7ar)-7-methyl-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,5,6,7a-tetrahydrocyclopenta[c]pyran-4a,5,7-triol Chemical compound O([C@@H]1OC=C[C@@]2(O)[C@H](O)C[C@@]([C@@H]12)(O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XUWSHXDEJOOIND-YYDKPPGPSA-N 0.000 claims description 15
- IFPWDIMCTSSWCJ-UHFFFAOYSA-N harpagide Natural products CC1(CC(O)C2(O)C=COCC12)OC3OC(CO)C(O)C(O)C3O IFPWDIMCTSSWCJ-UHFFFAOYSA-N 0.000 claims description 15
- VELYAQRXBJLJAK-UHFFFAOYSA-N myoporoside Natural products C12C(C)(O)CC(O)C2C=COC1OC1OC(CO)C(O)C(O)C1O VELYAQRXBJLJAK-UHFFFAOYSA-N 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 206010046766 uterine cancer Diseases 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- DTHRMEYEJGYKKG-UHFFFAOYSA-N Ajugoside Natural products CC(=O)OC1(C)CC(O)C2C=COC(OC3OC(CO)C(O)C(O)C3O)C12C DTHRMEYEJGYKKG-UHFFFAOYSA-N 0.000 claims description 4
- CAFTUQNGDROXEZ-XBDCZORHSA-N [(1s,4as,5r,7s,7as)-4a,5-dihydroxy-7-methyl-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,5,6,7a-tetrahydrocyclopenta[c]pyran-7-yl] acetate Chemical compound O([C@@H]1OC=C[C@@]2(O)[C@H](O)C[C@]([C@@H]12)(C)OC(=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CAFTUQNGDROXEZ-XBDCZORHSA-N 0.000 claims description 4
- CAFTUQNGDROXEZ-UHFFFAOYSA-N acetyl harpagide Natural products C12C(OC(=O)C)(C)CC(O)C2(O)C=COC1OC1OC(CO)C(O)C(O)C1O CAFTUQNGDROXEZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000003203 everyday effect Effects 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 208000017667 Chronic Disease Diseases 0.000 claims description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 239000007900 aqueous suspension Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000001647 drug administration Methods 0.000 claims description 2
- 239000000469 ethanolic extract Substances 0.000 claims description 2
- -1 loose Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 abstract description 27
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract description 17
- 238000011552 rat model Methods 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 13
- 241000588724 Escherichia coli Species 0.000 abstract description 7
- 230000008859 change Effects 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 238000000518 rheometry Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 50
- 230000008961 swelling Effects 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 210000001672 ovary Anatomy 0.000 description 10
- 210000004696 endometrium Anatomy 0.000 description 9
- 210000000981 epithelium Anatomy 0.000 description 9
- 231100000915 pathological change Toxicity 0.000 description 8
- 230000036285 pathological change Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 229960003742 phenol Drugs 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 230000000762 glandular Effects 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 206010020565 Hyperaemia Diseases 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 206010046798 Uterine leiomyoma Diseases 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000004145 Endometritis Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 241001528553 Malus asiatica Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
- 101800000989 Oxytocin Proteins 0.000 description 2
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 208000007893 Salpingitis Diseases 0.000 description 2
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 229960001723 oxytocin Drugs 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 241000762515 Hydrosalpinx Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 206010051458 Myometritis Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 244000173166 Pyrus ussuriensis Species 0.000 description 1
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010054824 Tubo-ovarian abscess Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000004712 cancer cell adhesion Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000006153 eosin methylene blue Substances 0.000 description 1
- 230000008508 epithelial proliferation Effects 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000030843 hydrosalpinx Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960003666 liquefied phenol Drugs 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940080119 ofloxacin 200 mg Drugs 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- JHJUUEHSAZXEEO-UHFFFAOYSA-M sodium;4-dodecylbenzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1 JHJUUEHSAZXEEO-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to new uses of an Ajuga ciliata Bunge extract, particularly to applications of the Ajuga ciliata Bunge extract in preparation of drugs for prevention and treatment of gynecological inflammatory diseases. According to the present invention, experimental results show that the gynecological inflammation treatment effects of the Ajuga ciliata Bunge extract on the two chronic pelvic inflammatory disease rat models caused by escherichia coli and phenol paste are verified, wherein the change of the blood rheology, the inflammatory factors and other indicators of the chronic pelvic inflammatory disease rat model caused by the phenol paste are observed after using the Ajuga ciliata Bunge extract, the change of the immunology indicator of the chronic pelvic inflammatory disease rat model caused by the escherichia coli is observed after using the Ajuga ciliata Bunge extract, and the intervention effects of the Ajuga ciliata Bunge extract on the uterus tissue inflammatory infiltration caused by chronic inflammations, tissue adhesion, and inflammatory mass caused by attachment hyperblastosis and the like are observed, such that the Ajuga ciliata Bunge extract provides the treatment effects on the long-term chronic inflammations and the attachment hyperblastosis caused by the long-term chronic inflammations.
Description
Technical field
The present invention relates to the novelty teabag of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract, be specifically related to the application of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract in the medicine of preparation treatment pelvic inflammatory disease.
Background technology
Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract, is shown in that CN200510085017.2(publication number is CN1899367A), the patent application disclose a kind of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract, Preparation method and use, wherein:
Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract is prepared by following methods: using Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) coarse powder as raw material, with water or concentration lower than 80% ethanol, heating extraction is carried out at 30-90 DEG C, or carry out percolation, it is 1.0-1.3 that extracting solution is concentrated into proportion, filter, through macroporous adsorbent resin process, after washing removing impurity, wash out completely to effective ingredient with the alcoholic solution eluting resin of 30-95%, recycling design, drying, obtains said extracted thing; Or (2) using Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) coarse powder as raw material, be 40-95% ethanol extraction by concentration, it is after 1.0-1.3 that extracting solution is concentrated into proportion, returns molten with the alcoholic solution of water or 5-30%, dissolution fluid is filtered, recycling design, dry, obtain said extracted thing.The effective part group of this extract is 8-acetyl group Harpagide (8-O-acetylharpagide) and Harpagide (Harpagide), and in extract, content is 50-99%, and the proportion of Harpagide and 8-acetyl group Harpagide is within the scope of 1:2-4.
The purposes of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract: be mainly used in cyclomastopathy, hysteromyoma, the two pathogenic factor is that spirit is in tension for a long time.For cyclomastopathy, applicant injects with Progesterone after 25 days with intramuscular injection estradiol benzoate, obtain hyperplasia of mammary gland model, confirm through experiment, the Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract that this patent provides can make cyclomastopathy alleviate, reduce degree and the breast wt of cyclomastopathy, reduce the level of estradiol (E2), reduce Uterine coefficient; Have obvious inhibitory action to the experimental hysteromyoma model of rat caused by estrogen, progestogen and Cavia porcellus, can reduce the uterus weight that model causes increases, under making uterus subangle, subangle root transverse diameter and uterine smooth muscle less thick; Reduce estrogen (estradiol) level; The congested swelling of animal uterus and the pathologic of uterine cancer cell is suppressed to change; Increase the shrinkage amplitude of rabbit Uterus in vivo; Rat granuloma is suppressed to swell and mice ear; Oxytocin, chemical stimulation and thermostimulation is suppressed to cause the pain reaction of mice.Above-mentioned model all adopts the mode of estradiol and Progesterone injection to carry out.
Pelvic inflammatory disease and inflammatory pelvic disease (Pelvic inflammatory disease, PID) are the one group of diseases caused by urogenital tract infection in women, comprise endometritis, salpingitis, tubo-ovarian abscess and pelvioperitonitis.Majority take pain as main manifestations, accounts for more than 90%.
About the diagnosis of PID, minimum diagnostic criteria is: uterus tenderness; Or adnexa tenderness; Or lifting pain.The treatment of PID, at present based on antibiotic anti-infective therapy, row operative treatment if desired.
At present, there is not yet the report of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract in treatment pelvic inflammatory disease.
Summary of the invention
The object of this invention is to provide a kind of novelty teabag of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract.
The invention provides the application of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract in the medicine preparing prevention and therapy gynecological inflammatory diseases.
Described Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract is water extract or the ethanol extract of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.), it contains 8-acetyl group Harpagide (8-O-acetylharpagide) and the Harpagide (Harpagide) of 50-99% weight, and the proportion of Harpagide and 8-acetyl group Harpagide is within the scope of 1:2-4;
Described gynecological inflammatory diseases is pelvic inflammatory disease, is preferably chronic pelvic inflammatory disease;
Described chronic pelvic inflammatory disease be long-term chronic inflammation show enclosure group and knit the inflammatory mass that hypertrophy is pathological characters.
Described chronic pelvic inflammatory disease is uterine cancer cell inflammatory infiltration caused by chronic inflammatory disease, tissue adhesion's chronic diseases becomes.
Described medicine is made up separately of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract or is made up of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract and pharmaceutically acceptable carrier.
Described medicine is peroral dosage form, drug administration by injection, topical, buccal administration, or by the administration of implantable medicine box.
Medicine of the present invention is preferably peroral dosage form, comprises, but is not limited to, capsule, tablet, ball, loose, water suspension or solution; Be preferably topical, comprise external suppository.
Described pharmaceutically acceptable carrier refers to the pharmaceutical carrier of pharmaceutical field routine, is selected from one or more in filler, binding agent, disintegrating agent, lubricant, solubilizing agent, suspending agent, wetting agent, pigment, essence, solvent, surfactant or correctives.
Described filler is selected from starch, pregelatinized Starch, dextrin, glucose, sucrose, lactose, lactose, microcrystalline Cellulose, mannitol, sorbitol or xylitol, preferred sorbitol, microcrystalline Cellulose, lactose or pregelatinized Starch;
Described disintegrating agent is selected from cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium or starch, preferred polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose or carboxymethyl starch sodium;
Described lubricant is selected from magnesium stearate, Pulvis Talci, micropowder silica gel, PEG4000, PEG6000, sodium laurylsulfate, preferred magnesium stearate, Pulvis Talci;
Described binding agent is selected from sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, polyvidone, starch slurry, sucrose, Icing Sugar, rubber cement, gelatin, Polyethylene Glycol, preferred hydroxypropyl methylcellulose, polyvidone;
Described solubilizing agent is selected from sodium hydroxide, potassium hydroxide, sodium bicarbonate, meglumine, 1B, L-arginine, preferred sodium hydroxide, meglumine;
Described suspending agent is selected from micropowder silica gel, Cera Flava, cellulose, solid polyethylene glycol;
Described wetting agent is selected from glycerol, tween 80, ethoxy aluminium Oleum Ricini or lecithin;
Described solvent selected from ethanol, liquid polyethylene glycol, isopropyl alcohol, tween 80, glycerol, propylene glycol or vegetable oil, described vegetable oil is selected from soybean oil, Oleum Ricini, Oleum Arachidis hypogaeae semen, mediation wet goods;
Described surfactant is selected from smooth or Polysorbate (tween) of dodecylbenzene sodium sulfonate, stearic acid, Pluronic F68, fatty acid Pyrusussuriensis etc.;
Described correctives is selected from aspartame, Sucralose, essence, steviosin, acesulfame potassium, citric acid or saccharin sodium.
Present invention also offers the use amount of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract, human body consumption every day 1-5 time; Each consumption is 1-30mg/kg body weight, and each consumption is preferably 2-10mg/kg; Each consumption more preferably 5mg/kg.
The novelty teabag of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) provided by the invention has the following advantages:
1, in prior art, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract is for cyclomastopathy and hysteromyoma, and the cause of disease of these two kinds of diseases is that disorder of hormone secretion causes, and chronic pelvic inflammatory disease refers to that reproductive tract infection causes the general name of chronic inflammation disease.Pelvic inflammatory disease comprises endometritis, myometritis, adnexitis, inflammation of pelvic connective tissue etc.Endometritis is the one of pelvic inflammatory disease, the inflammation of other internal organs of pelvic cavity can be caused again because of its up infection, after inflammation transfers chronic phase to, pus becomes hydrosalpinx or fallopian tube, ovarian cyst, and chronic pelvic paramitritis can form uterus, bilateral salpingo becomes lump with ovary adhesion.These are obviously different from the pathogenesis of cyclomastopathy and hysteromyoma.Therefore, cannot learn whether Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract can be used for pelvic inflammatory disease by prior art.
2, experimental result display, inventor sticks with paste on caused two kinds of rat chronic pelvic inflammatory disease models escherichia coli and phenol and demonstrates the drug effect of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract in treatment gynecological inflammation, wherein sticks with paste on caused rat chronic pelvic inflammatory disease model at phenol and observed the change of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract to indexs such as rat model hemorheology and inflammatory factors; On rat chronic pelvic inflammatory disease model caused by escherichia coli, observed the change of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) to rat model amynologic index; On above-mentioned two kinds of chronic pelvic inflammatory disease models, inventor observes Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract and becomes uterine cancer cell inflammatory infiltration caused by chronic inflammatory disease, tissue adhesion's chronic diseases and have intervention effect, in a word, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract has therapeutical effect to the inflammatory mass that long-term chronic inflammation and caused adnexa hamartoplasia thereof are pathological characters, therefore, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract has therapeutical effect to chronic pelvic inflammatory disease.
Accompanying drawing explanation
Fig. 1-Fig. 3 is that Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract causes the impact of rat pelvic inflammatory disease model to escherichia coli, wherein:
Fig. 1: sham operated rats, HE X400, glandular epithelium has no hypertrophy;
Fig. 2: model group, HE X400, the obvious hypertrophy of glandular epithelium, thickens;
Fig. 3: administration group (middle dosage group), HE X400, adenomatosis alleviates, slight cell infiltration;
Fig. 4-Fig. 6 is that Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract Pyrogentisinic Acid sticks with paste the impact causing rat pelvic inflammatory disease model, wherein:
Fig. 4: sham operated rats, HE X400, has no cell infiltration;
Fig. 5: model group, HE X400, inflammatory cell severe infiltrates;
Fig. 6: middle dosage group, HE X400, hypertrophy that glandular epithelium is slight.
Detailed description of the invention
Following examples for illustration of the present invention, but are not used for limiting the scope of the invention.
In following experimental example, following experiment material is all adopted to carry out:
1, laboratory animal:
Rat: Wistar kind, female, body weight 200 ± 20 grams, SPF level; SD kind, male, body weight 160+10 gram, SPF level; Above-mentioned animal is all purchased from Beijing Vital River Experimental Animals Technology Co., Ltd..
2, Experimental agents:
Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract: every ml extract, containing Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) crude drug 40 grams (every g is containing 8-O-Acetylharpagide 700mg), is provided by Beijing Kangchen Medicine Co., Ltd.Be divided into three dosage groups, wherein heavy dose of group (60-120mg/kg), middle dosage group (30-60mg/kg), small dose group (10-30mg/kg).
HUAHONG PIAN: Huahong Pharmaceutical Co., Ltd., Guangxi produces.
Ofloxacin: every sheet is containing ofloxacin 200mg, and Beijing the 4th pharmaceutical factory produces.
Placenta interstitial fluid: 5ml/ props up, Xiangtan, Hunan Province city pharmacy two factory produces.
Aspirin tablet: Bailu Pharmaceutical Co., Ltd., Shaanxi produces.
Diethylstilbestrol: 1mg/ml, Shanghai the 9th pharmaceutical factory produces.
Oxytocin inj: 10U/ml, Shanghai No.1 Bio-Chemical Pharmacetical Industry Co., Ltd.
Heparin sodium (Heparin Sodium, Chemical Reagent Co., Ltd., Sinopharm Group).
Tumor necrosis factor-alpha (TNF-α) radioimmunological kit, interleukin-6 (IL-6) radioimmunological kit, interleukin-1 beta (IL-1 β) radioimmunological kit, PGE2 (PGE2) radioimmunological kit produced by Beijing China English biotechnology research.
Hydroxybenzene mucilage: liquefied carbolic acid 5ml, tragacanth 1g, glycerol 4ml, adding distil water is to 20ml.Method for making: get tragacanth and be placed in drying receptacle, glycerol adding grinds, and adds liquefied phenol and distilled water gradually after making it fully mix, and it is for subsequent use to grind to form even rubber cement.
3, strain
Escherichia coli clinical separation strain: provided by Affiliated Hospital of Peking University first Bacteriology Room and identified.
Broth bouillon: Hangzhou microbial product factory produces.Eosin methylene blue agar: Haidian District, Beijing City microbiological culture media products factory is produced.
4, statistical method: continuous data adds standard deviation with mean and represents, is expressed as:
add up with t inspection between group, two groups of homogeneitys test of variance (F inspection) are done to data.
Experimental example 1: inhibitory action coli-infection being caused to rat chronic pelvic inflammatory disease model
1, experiment grouping: the animal except sham operated rats is divided into model group, positive drug 1 group and positive drug 2 groups, the large, medium and small dosage group of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract at random, often organizes 10.
2, strain preparation: the escherichia coli after going down to posterity through mice are joined broth bouillon (Carnis Bovis seu Bubali cream 0.3 gram, peptone 1.0 grams, NaCl0.5 gram, 100 milliliters, water, pH7.0-7.2, add water in beaker, take Carnis Bovis seu Bubali cream, peptone and NaCl, after heating is dissolved, adjust ph is to 7.0-7.2.Subpackage, adds tampon, high pressure steam sterilization) in, cultivate 7 hours through 37 DEG C of incubators, get 0.1ml bacterium liquid and join in 10ml nutrient broth medium, continue cultivation 17 hours, with physiological saline solution nephelometer number before using, be diluted to 1 × 10
7/ ml, for subsequent use.
3, the preparation of model: get rat pentobarbital sodium intraperitoneal injection of anesthesia, open abdomen under aseptic condition, exposes left uterine, and with injection to the modeling of endometrial tissue injection 0.2ml bacterium liquid, sham operated rats other steps except not injecting bacterium liquid are the same.
4, administration: after modeling 50 days, animal except sham operated rats is divided at random model group, positive drug 1 group, the large, medium and small dosage group of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract, often organize 10, according to the gastric infusion respectively of the dosage in table 1, positive control drug 1 group gives Ofloxacin, 10 times of the suitable clinical dosage of dosage, positive control drug 2 groups gives placenta interstitial fluid, the equal successive administration of each group 14 days, every day 1 time, administration volume is 0.5ml/100g, and sham operated rats and model group give consubstantiality hydrops.
5, Testing index: get hematometry T cell surface C D and break up subgroup level; With the difference of left and right sides uterus weight for swelling, calculate swelling rate and suppression ratio.
Swelling rate=[(left uterine weight-right uterine weight)/right uterine weight] × 100%;
Suppression ratio=[(the average swelling rate in model group uterus-average swelling rate in administration group the uterus)/average swelling rate in model group uterus] × 100%.
6, experimental result:
6.1 impacts on rat model uterus swelling
Table 1: on the impact of bacillary chronic pelvic inflammatory disease rat model uterus swelling rate
| Group | Dosage (mg extract/Kg) | Swelling (mg) | Swelling rate (%) | Suppression ratio (%) |
| Sham operated rats | -- | 0.69±3.03 | 0.57±2.22 | -- |
| Model group | -- | 38.42±7.96 ## | 24.32±7.04 ## | -- |
| Ofloxacin group | 67 | 14.30±0.45 ** | 10.22±3.47 ** | 57.98 |
| Heavy dose of group | 60 | 16.63±5.91 ** | 13.34±5.50 ** | 45.15 |
| Middle dosage group | 30 | 20.69±4.70 ** | 14.59±3.98 ** | 40.00 |
| Small dose group | 15 | 26.00±7.12 ** | 18.89±5.04 * | 22.33 |
Note: compare with sham operated rats, ##P<0.01; Compare with model group,
*p<0.01.
Table 1 result shows: compare with model group, each administration group rat uterus swelling and swelling rate are all in reducing to some extent, except Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) small dose group rat uterus swelling rate difference significantly except, all the other each administration group numerical value all reduce in significance, to the suppression ratio of uterus swelling between 45%-22%.
6.2 impacts on rat model T cell Surface Differentiation group (CD)
Table 2: the impact bacillary chronic pelvic inflammatory disease rat model T cell surface C D being broken up to group
Note: compare with sham operated rats: #P<0.05, ##P<0.01; Compare with model group:
*p<0.05,
*p<0.01.
Table 2 result shows, and compares, positive drug and Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract big or middle dosage group rat T cells Surface Differentiation group CD with model group
3 +, CD
4 +, CD
8 +level obviously raises, and low dose affects without significance CD cellular level.The T cell Surface Differentiation group CD of model group rats
3 +, CD
4 +and CD
8 +level obviously reduces, and especially represents the CD of body's immunity prosperity and decline
4 +cellular level declines, and prompting, bacillary chronic pelvic inflammatory disease rat model presents immunologic hypofunction state, after Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract intervention, show certain immunologic enhancement to rat model.
6.3 impacts on uterus pathomorphology
Visual results shows, and model control group rat portions uterus color is dark red, cervix uteri obvious tumefaction, hyperemia, and adhesion that individual animal abdominal cavity is slight, ovary shows no obvious abnormalities.Positive drug and Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract large, medium and small dosage group rat uterus swollen neck is swollen, hyperemia all has and alleviates in various degree, ovary shows no obvious abnormalities.
Microscopic observation result shows, and rats in sham-operated group uterine epithelium has no hypertrophy, thickens, and body of gland has no pathological changes, and inner membrance has no and thickens, and ovary has no obvious pathological changes (see figure 1).The obvious hypertrophy of model control group rat endometrium glandular epithelium, thicken, epithelium number of plies showed increased, mitosis figures is more common, epithelial cell has degeneration necrosis, and in flat, the lymphocyte of upper subcutaneous hypertrophy is more, under major part endometrium, neutral leaflet core comparatively fills the air, and what have reaches myometrium.Bilateral ovaries and endometrial gland are there are no obvious pathological changes (see figure 2).Under Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract big or middle dosage group rat endometrium, inflammatory cell infiltration obviously alleviates, and has mild inflammatory cellular infiltration under small dose group rat endometrium, and in comparatively typical, Fig. 3 is shown in by the picture of dosage group.
Experimental example 2: Pyrogentisinic Acid's paste causes the inhibitory action of rat pelvic inflammatory disease inflammatory adhesion model
1, on the impact of inflammatory factor
1.1 experimental techniques: get rat, 10 are left and taken at random as Sham-operated control group according to body weight, all the other rats, with pentobarbital sodium intraperitoneal injection of anesthesia, fix animal, routine disinfection, open abdomen, expose uterus, from the crosslinked place of bilateral uterine, syringe needle carefully thrusts left uterine chamber, slowly inject phenol paste 0.04ml.Rats in sham-operated group other steps except phenol paste is not injected in uterus are the same.
1.2 experiment grouping and administrations: after modeling 15 days, animal except sham operated rats is divided into model group, positive drug ofloxacin group, positive drug HUAHONG PIAN group, the large, medium and small dosage group of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract 6 groups at random according to body weight, often organize 10, according to the gastric infusion respectively of dosage in table 4, successive administration 14 days, every day 1 time, administration volume is 1ml/100g.
1.3 Testing index: abdominal aortic blood, measure IL-6 and PGE2 level and TNF-alpha levels.
1.4 testing results: in table 3
Table 3: Pyrogentisinic Acid's paste causes the impact of pelvic inflammatory disease rat model inflammatory factor
Note: compare with sham operated rats: ##P<0.01; Compare with model group:
*p<0.05;
*p<0.01.
Table 3 result shows, and compare with model group, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract large, medium and small dosage group rat uterus tissue TNF-a level all has obvious reduction, and rat blood serum IL-6 level all has reduction trend in obviously reducing rat blood serum PGE2 level
3, on the impact organizing general form
3.1 Testing index: after dissecting, vagina to the uterus histomorphology of each treated animal of light Microscopic observation changes and mucosa, the morphologic inflammatory infiltration degree of interstitial under mucosa.
3.2 testing results: after dissecting, perusal is visible, rats in sham-operated group uterus color, hardness are normal, and cervix uteri has no swelling, hyperemia.Model group rats part uterus darker in color is red, cervix uteri obvious tumefaction, hyperemia, adhesion that individual animal abdominal cavity is slight.Compared with model group, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) each dosage group rat uterus swollen neck is swollen, congested and have alleviate in various degree with the adhesion degree around abdominal cavity, and ovary is showed no obvious abnormalities.
4, on the impact of Pathomorphologic
The result display of 4.1 Microscopic observations, rats in sham-operated group endometrium has no and obviously thickens, intimal surface epithelium or have slight hypertrophy, and body of gland has no pathological changes, and interstitial, except intiltration of acidophilic leukocyte, has no obvious lymphocytic infiltration (see figure 4).The obvious hypertrophy of model control group rat endometrium, to thicken, intimal surface epithelial proliferation, mitosis figures is more common, between epithelial cell, time see apoptotic body and visible more fragment, to severe cell infiltration in visible in interstitial, to be above subcutaneously dispersed in or stove shape lymphocyte, neutrophil infiltration, sometimes to see that cell infiltration is around inner membrance body of gland or in lumen of gland.Bilateral ovaries is there are no obvious pathological changes (see figure 5).Heavy dose of group rat endometrium hypertrophy, thicken comparatively model group and have and alleviate to a certain extent, upper subcutaneously have slight cell infiltration, and ovary has no obvious pathological changes.Middle dosage group rat endometrium epithelial cell has slight hypertrophy, and ovary has no obvious pathological changes.Small dose group rat endometrium epithelium has hypertrophy, upper subcutaneous cell infiltration, more obvious individually.Each administration group rat ovary is showed no obvious pathological changes (be comparatively typically middle dosage group, see Fig. 6).
The summary of experimental example 1,2:
To result of the test display that is bacillary and phenol paste property two kinds of rat chronic pelvic inflammatory disease models, the large, medium and small dosage of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract can obviously suppress the uterus swelling caused by this model to increase, obvious suppressor T cell Surface Differentiation group CD
+ 3, CD
+ 4, CD
+ 8the reduction of level, obviously suppresses endometrial glandular epithelia hypertrophy, thickens and change with the pathologic such as inflammatory infiltration; Obviously can reduce shear rate is 150s simultaneously
-1, 38s
-1, 10s
-1and 5s
-1time rat model whole blood viscosity and reduced viscosity, obviously reduce rat model uterine cancer cell inflammatory factor TNF-α and IL-6, under obvious inhibition rat uterus mucous epithelium hypertrophy and mucosa, the pathologic such as inflammatory cell infiltration changes.Prompting, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract to rat chronic pelvic inflammatory disease models show antiinflammatory, reduce blood viscosity and increase the effect of body's immunity, chronic inflammation model is caused uterine cancer cell adhesion, hypertrophy and thickened there is obvious therapeutical effect.
Although above with general explanation, detailed description of the invention and test, the present invention is described in detail, and on basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, all belong to the scope of protection of present invention.
Claims (10)
1. the application of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract in the medicine preparing prevention and therapy gynecological inflammatory diseases.
2. application according to claim 1; it is characterized in that; described Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract is water extract or the ethanol extract of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.); described Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract contains 8-acetyl group Harpagide (8-O-acetylharpagide) and the Harpagide (Harpagide) of 50-99% weight, and the proportion of Harpagide and 8-acetyl group Harpagide is within the scope of 1:2-4.
3. application according to claim 1 and 2, is characterized in that, described gynecological inflammatory diseases is pelvic inflammatory disease.
4. application according to claim 3, is characterized in that, described pelvic inflammatory disease is chronic pelvic inflammatory disease.
5. application according to claim 4, is characterized in that, described chronic pelvic inflammatory disease be long-term chronic inflammation and show enclosure group and knit the inflammatory mass that hypertrophy is pathological characters.
6. application according to claim 4, is characterized in that, described chronic pelvic inflammatory disease is chronic inflammatory disease and caused uterine cancer cell inflammatory infiltration thereof, tissue adhesion's chronic diseases becomes.
7. the application according to any one of claim 1-6, is characterized in that, described medicine is made up separately of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract or is made up of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract and pharmaceutically acceptable carrier.
8. application according to claim 7, is characterized in that, described medicine is peroral dosage form, drug administration by injection, topical, buccal administration, or by the administration of implantable medicine box.
9. application according to claim 8, is characterized in that, described peroral dosage form is capsule, tablet, ball, loose, water suspension or solution; Described topical is external suppository.
10. the application according to any one of claim 1-6, is characterized in that, the use amount of Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) extract, human body consumption every day 1-5 time; Each consumption is 1-30mg/kg body weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310541149.6A CN104606284A (en) | 2013-11-05 | 2013-11-05 | New uses of Ajuga ciliata Bunge extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310541149.6A CN104606284A (en) | 2013-11-05 | 2013-11-05 | New uses of Ajuga ciliata Bunge extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104606284A true CN104606284A (en) | 2015-05-13 |
Family
ID=53141104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310541149.6A Pending CN104606284A (en) | 2013-11-05 | 2013-11-05 | New uses of Ajuga ciliata Bunge extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104606284A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111973652A (en) * | 2019-05-23 | 2020-11-24 | 法玛科技顾问股份有限公司 | Method for treating cell aging |
| CN111990571A (en) * | 2020-09-02 | 2020-11-27 | 蔡晓明 | Inflammation-dispelling and blood circulation-promoting functional beverage and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1425436A (en) * | 2002-12-26 | 2003-06-25 | 复旦大学附属妇产科医院 | Traditional Chinese medicine preparation for curing gynecopathy |
| CN1895361A (en) * | 2006-06-19 | 2007-01-17 | 上海慈瑞医药科技有限公司 | Chinese-medicinal composition for treating gynecological inflammation and its preparation |
| WO2007059441A2 (en) * | 2005-11-10 | 2007-05-24 | Jose Angel Olalde Rangel | Synergistic phytoceutical compositions |
| CN1899367B (en) * | 2005-07-19 | 2010-12-01 | 中国中医科学院中药研究所 | Carpet bugle extract, its preparing method, use and compound preparation |
| CN102603826A (en) * | 2011-01-20 | 2012-07-25 | 中国中医科学院中药研究所 | Method for extracting 8-acetylharpagide from decumbent bugle herb plant |
-
2013
- 2013-11-05 CN CN201310541149.6A patent/CN104606284A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1425436A (en) * | 2002-12-26 | 2003-06-25 | 复旦大学附属妇产科医院 | Traditional Chinese medicine preparation for curing gynecopathy |
| CN1899367B (en) * | 2005-07-19 | 2010-12-01 | 中国中医科学院中药研究所 | Carpet bugle extract, its preparing method, use and compound preparation |
| WO2007059441A2 (en) * | 2005-11-10 | 2007-05-24 | Jose Angel Olalde Rangel | Synergistic phytoceutical compositions |
| CN1895361A (en) * | 2006-06-19 | 2007-01-17 | 上海慈瑞医药科技有限公司 | Chinese-medicinal composition for treating gynecological inflammation and its preparation |
| CN102603826A (en) * | 2011-01-20 | 2012-07-25 | 中国中医科学院中药研究所 | Method for extracting 8-acetylharpagide from decumbent bugle herb plant |
Non-Patent Citations (3)
| Title |
|---|
| BINYU WEN等: "Pharmacokinetics of 8-O-acetylharpagide and harpagide after oral administration of Ajuga decumbens Thunb extract in rats", 《JOURNAL OF ETHNOPHARMACOLOGY》 * |
| 温彬宇等: "筋骨草提取物有效成分在beagle犬体内药代动力学研究", 《中国中药杂志》 * |
| 陈芳等: "筋骨草抗炎有效部位及其量效关系研究", 《福建中医学院学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111973652A (en) * | 2019-05-23 | 2020-11-24 | 法玛科技顾问股份有限公司 | Method for treating cell aging |
| CN111990571A (en) * | 2020-09-02 | 2020-11-27 | 蔡晓明 | Inflammation-dispelling and blood circulation-promoting functional beverage and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105919926B (en) | A kind of Carbomer cervical gel and preparation method thereof | |
| CN102698292A (en) | Preparation method of animal model simulating human pelvic inflammatory disease (PID) | |
| CN114209810B (en) | Application of lycium barbarum glycopeptide in preparation of medicine for preventing or treating inflammatory bowel disease | |
| CN104606284A (en) | New uses of Ajuga ciliata Bunge extract | |
| CN102302505B (en) | Medicinal composition for treating pelvic inflammatory disease and application thereof | |
| CN109512851B (en) | Preparation method of medical antibacterial midwifery gel | |
| CN112716948A (en) | Application of dihydroberberine in preparing medicine for treating ulcerative colitis | |
| CN110693895A (en) | Pharmaceutical composition for treating hemorrhoids and preparation thereof | |
| CN100464745C (en) | Medication composition of acetyl cysteine or its pharmaceutical salt and asarin | |
| CN103070948B (en) | Pharmaceutical composition for treating eye diseases and preparation method | |
| CN101327304A (en) | Use of Ningbingtai in medicament for treating gynecology inflammation | |
| CN105362325A (en) | Traditional Chinese medicine chrysanthemum indicum extract and preparation method, pharmaceutical composition and application thereof | |
| CN107308221B (en) | New application of Feiyang gastroenteritis capsule in treating pelvic inflammatory sequelae | |
| CN107854540B (en) | External traditional Chinese medicine formula essential oil for treating haemorrhoids | |
| CN103655545B (en) | The application of Jaceosidin in the medicine preparing treatment or preventing chronic injury of kidney | |
| CN103656084B (en) | It is a kind of to treat pharmaceutical composition of chronic pelvic inflammatory disease and preparation method thereof | |
| CN107485655B (en) | Application of peach blossom extract in preparation of medicine for treating prostatitis | |
| CN104042879A (en) | Traditional Chinese medicine granules for reversing precancerous lesions of chronic atrophic gastritis and preparation method thereof | |
| CN110917198B (en) | Application of dehydroevodiamine in preparation of medicine for treating acute gastritis | |
| CN104887793B (en) | A kind of coptis chinensis total alkaloid vaginal plug | |
| CN1318061C (en) | Method for preparing medicine | |
| CN1183952C (en) | Medicine for treating uterus myoma disease and its preparation method | |
| CN115350185B (en) | Application of domperidone in preparation of medicine for treating ulcerative colitis | |
| CN114712351B (en) | Application of rhynchophylline in preparation of medicines for treating inflammatory enteritis | |
| CN102139071A (en) | Chinese medicinal soft capsule for treating gynecological inflammation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: KANGCHEN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING KONRUNS PHARMACEUTICAL CO., LTD. Effective date: 20150728 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 100085 Miyun Economic Development Zone, Beijing, No. 11 South Road Applicant after: BEIJING KONRUNS PHARMACEUTICAL Co.,Ltd. Address before: 100085, A, building 7, building 9, Wah Wah building, 708 3rd Street, Beijing, Haidian District Applicant before: BEIJING KONRUNS PHARMACEUTICAL Co.,Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100085 HAIDIAN, BEIJING TO: 100085 MIYUN, BEIJING |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150728 Address after: 100085, room 712, building A, Ka Wah building, No. 9, 3rd Street, Haidian District, Beijing Applicant after: Konruns Pharmaceutical Co.,Ltd. Address before: 100085 Miyun Economic Development Zone, Beijing, No. 11 South Road Applicant before: BEIJING KONRUNS PHARMACEUTICAL Co.,Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160321 Address after: 101500 Miyun Economic Development Zone, Beijing, No. 11 South Road Applicant after: BEIJING KONRUNS PHARMACEUTICAL Co.,Ltd. Address before: 100085, room 712, building A, Ka Wah building, No. 9, 3rd Street, Haidian District, Beijing Applicant before: Konruns Pharmaceutical Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150513 |